tiprankstipranks
Trending News
More News >

Essa Pharma downgraded to Hold from Buy at JonesResearch

JonesResearch analyst Soumit Roy downgraded Essa Pharma (EPIX) to Hold from Buy with no price target after the board decided to terminate all trials to conserve cash. The firm, which says “we were wrong in our assessment of masofaniten’s potential,” expects the stock to trade at a 40%-50% discount to cash per share of $2.64 and awaits comments from management on the future steps they plan.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue